![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Posts
;
@ASCO brings research to the forefront.
On Day 1 of #ASCO25, we’re highlighting the INDICATE trial, which explores genomic testing to guide post-surgery therapy decisions in prostate cancer.
Watch the IRB-approved video:
https://www.primrmed.com/cancer-clinical-trials/indicate-trial
@eaonc
Great work to @MethodistHosp Sugar Land Hospital for enrolling their first patient in #ClinicalTrial EA5182! This study is exploring osimertinib +/- bevacizumab as initial treatment for pts with EGFR-mutant #LungCancer. Learn more: #lcsm
Trial Spotlight: Helena Yu Gives an Update on the EA5182 Trial for EGFR-Mutant Non-Small Cell Lung...
This phase 3 randomized controlled trial is comparing first-line treatment with osimertinib plus bevacizumab versus osim...
bit.ly
If you’re 18–39 and recently finished treatment for lymphoma, you may be eligible to join a study that could make a positive impact on the adolescent and young adult (AYA) cancer community. Sign up 👉 https://bit.ly/4jkGt93
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
37
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
